Despite significant enthusiasm for CD47 targeting pathways given the therapeutic rationale and early clinical data, further trials to date across the spectrum of non-PTCL hematologic malignancies have not wholly delivered on this promise due to perceived lack of efficacy and/or potential toxicities, including significant anemia [33]. The gene discussed is CD47; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.